# A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

> **NCT06711640** · PHASE1 · WITHDRAWN · sponsor: **USWM, LLC (dba US WorldMeds)**

## Conditions studied

- Opioid Withdrawal (Disorder)
- Opioid Use Disorder

## Interventions

- **DRUG:** LUCEMYRA (lofexidine) tablets

## Key facts

- **NCT ID:** NCT06711640
- **Lead sponsor:** USWM, LLC (dba US WorldMeds)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06
- **Primary completion:** 2026-01
- **Final completion:** 2026-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn prior to enrollment due to strategic portfolio decisions following divestiture of the investigational product.
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06711640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06711640, "A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06711640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*